Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13170602 | 0.70 | — | — | |
| SCHEMBL19366633 | 0.69 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2TSHRATMMAPT | |
| SCHEMBL12170337 | 0.62 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL13180796 | 0.61 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL14084443 | 0.61 | AAK1 (0.31) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2757596 | 0.61 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL423531 | 0.60 | MEN1 (0.60) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL19366625 | 0.58 | DCTPP1 (0.36) | ALDH1A1SMN1; SMN2TSHRATMMAPT | |
| SCHEMBL19657080 | 0.58 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL13170606 | 0.58 | KDM4E (0.38) | ALDH1A1KDM4EMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ARCUS BIOSCIENCES, INC. | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267710-A1 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF | ENTPD5, NT5C2, NT5E | ALDH1A1 1449/4885SMN1; SMN2 3617/4885KDM4E 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.